ReviewExpert review of vaccines2019
Selection of adjuvants for vaccines targeting specific pathogens.
Review in Expert review of vaccines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 115 citations in OpenAlex.
- Nanomaterials for the Prevention, Detection, and Treatment of Pharyngeal Human Papillomavirus Infection: A Translational Roadmap.Materials (Basel, Switzerland) · 2026Review
- Evaluating immunoreactivity of hybridoma-derived antibody mixtures generated against AU-565 cell line for diagnosis and immunotherapy of breast cancer.BMC cancer · 2026Article
- Immunization with Herpes Simplex Virus Nanoparticles Targeting Both Attachment and Fusion Protect Against Infection.bioRxiv : the preprint server for biology · 2026Article
- Advances in functional transcriptome analysis of Mycobacterium tuberculosis: a review.Molecular genetics and genomics : MGG · 2026Review
- Adjuvant Strategies to Improve the Efficacy of Allergen Immunotherapy.Journal of inflammation research · 2026Review
- The impact of innate and humoral immune mechanisms on vaccine induced protection against avian influenza H9N2 in broilers.Scientific reports · 2025Article
- Advancing Tuberculosis Chemotherapy: Targeted Nanomedicines for the Mycobacterium TB Granuloma.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Review
- Article
- Challenges and opportunities on achieving an adequate delivery efficiency and immunogenicity with peptide-based anticancer vaccines.Advanced drug delivery reviews · 2025Review
- HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques.Nature communications · 2025Article
- Article
- Review
- In Silico Development of a Chimeric Multi-Epitope Vaccine TargetingPharmaceuticals (Basel, Switzerland) · 2025Article
- Genetic adjuvants: A paradigm shift in vaccine development and immune modulation.Molecular therapy. Nucleic acids · 2025Review
- Mucosal immunotherapy targeting APC in lung disease.Journal of inflammation (London, England) · 2025Review
- Antigen-Dependent Adjuvanticity of Poly(lactic-co-glycolic acid)-polyethylene Glycol 25% Nanoparticles for Enhanced Vaccine Efficacy.Vaccines · 2025Article
- Metabolic Reprogramming in Response to Freund's Adjuvants: Insights from Serum Metabolomics.Microorganisms · 2025Article
- Transcriptional profiles of vaccine-induced protection in bovine herpesvirus-1 andFrontiers in veterinary science · 2025Article
- Impact of lactobacillus probiotics on vaccine response in diabetic rats: modulation of inflammatory cytokines.American journal of clinical and experimental immunology · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
introductionAdjuvants form an integral component in most of the inactivated and subunit vaccine formulations. Careful and proper selection of adjuvants helps in promoting appropriate immune responses against target pathogens at both innate and adaptive levels such that protective immunity can be elicited. Areas covered: Herein, we describe the recent progress in our understanding of the mode of action of adjuvants that are licensed for use in human vaccines or in clinical or pre-clinical stages at both innate and adaptive levels. Different pathogens have distinct characteristics, which require the host to mount an appropriate immune response against them. Adjuvants can be selected to elicit a tailor-made immune response to specific pathogens based on their unique properties. Identification of biomarkers of adjuvanticity for several candidate vaccines using omics-based technologies can unravel the mechanism of action of modern and experimental adjuvants. Expert opinion: Adjuvant technology has been revolutionized over the last two decades. In-depth understanding of the role of adjuvants in activating the innate immune system, combined with systems vaccinology approaches, have led to the development of next-generation, novel adjuvants that can be used in vaccines against challenging pathogens and in specific target populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.